InSeal Vascular Closure Device Clinical Study Protocol

InSeal Medical Ltd.1 site in 1 country33 target enrollmentFebruary 2012

ConditionsPercutaneous Closure of Artery Access Sites

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Percutaneous Closure of Artery Access Sites
Sponsor: InSeal Medical Ltd.
Enrollment: 33
Locations: 1
Primary Endpoint: 1. Hemostasis within 15 minutes following vessel access site closure and after ACT falls below 200 second
Status: Terminated
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The InSeal vascular closure device (VCD)is assessed as percutaneous closure of artery access sites for quick hemostasis and ambulation in patients who have undergone large bore endovascular catheterization procedures.

The study hypothesis is that the VCD is safe and efficaient in achieving hemostasis in the study population.

Registry

clinicaltrials.gov

Start Date

February 2012

End Date

August 2015

Last Updated

10 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

InSeal Medical Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Candidate for large bore catheterization procedure (such as TAVI, aortic endograft repair) using a CE approved 18Fr access sheath.
•Subject age is at least 18 years
•Patient has signed most recent approved version of the Informed Consent
•Existence of an additional arterial access port is required in instances where an occluding balloon is planned to be used as a safety precaution.

Exclusion Criteria

•Women Of Child Bearing Potential (WOCBP)
•Legally non-competent patients
•Patient participating in another clinical study at the time of the InSeal VCD study
•Prior target artery closure with a vascular closure device having intravascular component (such as Angio-Seal) 30 days prior to catheterization
•Subjects with known coagulopathy, preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the vessel access site prior to artery closure
•Patients that do not tolerate aspirin and clopidogrel anticoagulation treatment
•Prior vascular surgery or vascular graft in region of access site
•Significant calcification, atherosclerotic disease, or stent within 1.5 cm of the puncture site that may interfere with the operation of the experimental device